Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/4/844 |
| _version_ | 1797571823507865600 |
|---|---|
| author | Kei Muro Taylor Salinardi Arvind Rup Singh Teresa Macarulla |
| author_facet | Kei Muro Taylor Salinardi Arvind Rup Singh Teresa Macarulla |
| author_sort | Kei Muro |
| collection | DOAJ |
| description | Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti-epidermal growth factor receptor (EGFR) therapies. Aflibercept, a recombinant fusion protein, has been approved for treatment of mCRC in combination with FOLFIRI for patients whose disease progresses during or after treatment with an oxaliplatin-containing regimen, based on its efficacy and tolerability profile in clinical trials. This report aims to provide an overview of both clinical and real-world evidence and experience on the use of aflibercept in routine clinical practice, with a focus on European, American and Asian populations. Methods: A literature search was conducted in PubMed (on 28th February 2019) using the search terms ("aflibercept") and ("Colorectal"OR"CRC") to identify publications containing information on aflibercept-containing regimens. Results: The adverse events (AE) profile was similar between geographical locations. Across trials, real-world and retrospective studies, grade ≥ 3 hypertension and proteinuria were amongst the most frequently reported AEs. Conclusions: The safety profile of aflibercept is generally manageable and comparable across various geographic locations. |
| first_indexed | 2024-03-10T20:46:06Z |
| format | Article |
| id | doaj.art-918796055b1a4671bc9b92e4a5b4fed7 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T20:46:06Z |
| publishDate | 2020-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-918796055b1a4671bc9b92e4a5b4fed72023-11-19T20:18:09ZengMDPI AGCancers2072-66942020-03-0112484410.3390/cancers12040844Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World DataKei Muro0Taylor Salinardi1Arvind Rup Singh2Teresa Macarulla3Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, JapanGlobal Medical Oncology, Sanofi, Boston, MA 02142, USAGlobal Medical Oncology, Sanofi, Boston, MA 02142, USAGastrointestinal Tumors Service of the Medical Oncology Service, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, IOB, Barcelona 08035, SpainBackground: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti-epidermal growth factor receptor (EGFR) therapies. Aflibercept, a recombinant fusion protein, has been approved for treatment of mCRC in combination with FOLFIRI for patients whose disease progresses during or after treatment with an oxaliplatin-containing regimen, based on its efficacy and tolerability profile in clinical trials. This report aims to provide an overview of both clinical and real-world evidence and experience on the use of aflibercept in routine clinical practice, with a focus on European, American and Asian populations. Methods: A literature search was conducted in PubMed (on 28th February 2019) using the search terms ("aflibercept") and ("Colorectal"OR"CRC") to identify publications containing information on aflibercept-containing regimens. Results: The adverse events (AE) profile was similar between geographical locations. Across trials, real-world and retrospective studies, grade ≥ 3 hypertension and proteinuria were amongst the most frequently reported AEs. Conclusions: The safety profile of aflibercept is generally manageable and comparable across various geographic locations.https://www.mdpi.com/2072-6694/12/4/844colorectal cancermCRCVEGF inhibitoranti-angiogenic therapyafliberceptclinical practice |
| spellingShingle | Kei Muro Taylor Salinardi Arvind Rup Singh Teresa Macarulla Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data Cancers colorectal cancer mCRC VEGF inhibitor anti-angiogenic therapy aflibercept clinical practice |
| title | Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data |
| title_full | Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data |
| title_fullStr | Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data |
| title_full_unstemmed | Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data |
| title_short | Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data |
| title_sort | safety of aflibercept in metastatic colorectal cancer a literature review and expert perspective on clinical and real world data |
| topic | colorectal cancer mCRC VEGF inhibitor anti-angiogenic therapy aflibercept clinical practice |
| url | https://www.mdpi.com/2072-6694/12/4/844 |
| work_keys_str_mv | AT keimuro safetyofafliberceptinmetastaticcolorectalcanceraliteraturereviewandexpertperspectiveonclinicalandrealworlddata AT taylorsalinardi safetyofafliberceptinmetastaticcolorectalcanceraliteraturereviewandexpertperspectiveonclinicalandrealworlddata AT arvindrupsingh safetyofafliberceptinmetastaticcolorectalcanceraliteraturereviewandexpertperspectiveonclinicalandrealworlddata AT teresamacarulla safetyofafliberceptinmetastaticcolorectalcanceraliteraturereviewandexpertperspectiveonclinicalandrealworlddata |